Indaptus Therapeutics (INDP) Earnings
Price: $0.47
Market Cap: $7.55M
Market Cap: $7.55M
Revenue (TTM): $-
Net Income: $-15.02M
Net Income: $-15.02M
P/E Ratio: -0.29
EPS (TTM): $-1.61
EPS (TTM): $-1.61
Earnings Dates
Indaptus Therapeutics (INDP) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 14, 2025
- Time of Day: Before Market Open
- Estimated EPS: $-0.41
Last Earnings Report
- Date: March 13, 2025
- EPS: $-0.38
- EPS Estimate: $-0.41
Indaptus Therapeutics's next earnings report is scheduled for May 14, 2025.
In its last earnings report on March 13, 2025, Indaptus Therapeutics reported earnings per share (EPS) of $-0.38, compared to an estimated EPS of $-0.41. The company reported revenue of $-, compared to an estimated revenue of $-.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| March 13, 2025 | $-0.38 | $-0.41 | $- | $- |
| November 12, 2024 | $-0.32 | $-0.47 | $- | $- |
| August 12, 2024 | $-0.47 | $-0.54 | $- | $- |
| May 08, 2024 | $-0.45 | $-0.57 | $- | $- |
| March 13, 2024 | $-0.47 | $-0.54 | $1.93K | $- |
| November 06, 2023 | $-0.47 | $-0.55 | $- | $- |
| August 14, 2023 | $-0.39 | $-0.58 | $- | $- |
| May 11, 2023 | $-0.51 | $-0.59 | $- | $- |
| March 17, 2023 | $-0.44 | $-0.52 | $- | $- |
| November 10, 2022 | $-0.42 | $-0.47 | $- | $- |
| August 08, 2022 | $-0.46 | $-0.43 | $- | $- |
| May 12, 2022 | $-0.41 | $-0.39 | $- | $- |
| March 21, 2022 | $-0.22 | $-0.90 | $- | $- |
| November 15, 2021 | $-0.81 | $-0.55 | $- | $- |
| August 16, 2021 | $-5.53 | $-2.56 | $- | $- |
| May 17, 2021 | $-3.84 | $-3.48 | $- | $- |
| March 16, 2021 | $-2.12 | $-3.40 | $- | $- |
| November 05, 2020 | $-3.80 | $-3.47 | $- | $- |
| August 05, 2020 | $-4.00 | $-4.27 | $- | $- |
Annual Earnings
Annual Revenue
$-
Fiscal Year 2024Annual Net Income
$-15.02M
Fiscal Year 2024Annual EPS
$-1.61
Fiscal Year 2024Quarterly Earnings
Revenue
$-
Quarter Ending December 31, 2024Net Income
$-4.13M
Quarter Ending December 31, 2024EPS
$-0.37
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-190.67%
Year Ending December 31, 2024P/E Ratio
-0.52
Year Ending December 31, 2024Revenue Per Share
$0.00
Year Ending December 31, 2024Earnings Yield (TTM)
-340.90%
Trailing Twelve MonthsP/E Ratio (TTM)
-0.29
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.00
Trailing Twelve MonthsFrequently Asked Questions
Indaptus Therapeutics's next earnings date is scheduled for May 14, 2025. The earnings call is expected to take place before market open.
In its last earnings report on March 13, 2025, Indaptus Therapeutics reported earnings per share (EPS) of $-0.38, compared to an estimated EPS of $-0.41. The company reported revenue of $-, compared to an estimated revenue of $-.
Indaptus Therapeutics's current Price-to-Earnings (P/E) ratio is -0.52. The trailing twelve months (TTM) P/E ratio is -0.29. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Indaptus Therapeutics reported total revenue of $- and net income of $-15.02M. This represents a net profit margin of None.
Indaptus Therapeutics's earnings yield is -190.67%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Indaptus Therapeutics's return on equity (ROE) is -380.80%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Indaptus Therapeutics's gross profit margin is 0.00%. This indicates that for every dollar of revenue, the company retains $0.00 as gross profit after accounting for the cost of goods sold.